VALIDATION OF AN ALGORITHM TO IDENTIFY HR+/HER2-METASTATIC BREAST CANCER IN CLAIMS DATA

被引：0
|
作者：
Chin, A. [1 ]
Ip, Q. [1 ]
Wu, X. [1 ]
Lyle, D. [2 ]
机构：
[1] Komodo Hlth, San Francisco, CA USA
[2] NeoGenomics, Ft Myers, FL USA
来源：
VALUE IN HEALTH | 2024年 / 27卷 / 06期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EPH56
引用
收藏
页码：S163 / S163
页数：1
相关论文
共 50 条
  • [31] Real-world comparative effectiveness of palbociclib plus aromatase inhibitor in HR+/HER2-metastatic breast cancer
    Robert, Nicholas
    Chen, Connie
    Kim, Sindy
    Zhang, Zhe
    Aguilar, Kathleen M.
    Wang, Yunfei
    Li, Benjamin
    Gaffney, Michael
    Huang, Xin
    Mcroy, Lynn
    FUTURE ONCOLOGY, 2024, 20 (12) : 761 - 780
  • [32] Ribociclib Improves Overall Survival in HR+/HER2-Metastatic Breast Cancer Across Common Genomic and Clinical Subtypes
    Jacobson, Anne
    ONCOLOGIST, 2022, 27 (SUPPL 1): : S11 - S12
  • [33] HEALTHCARE COSTS IN WOMEN WITH HR+/HER2-METASTATIC BREAST CANCER TREATED WITH CDK4/6 INHIBITORS
    Burne, R.
    Balu, S.
    Guerin, A.
    Liang, Y.
    Schloessmann, R.
    Bungay, R.
    Paul, M. L.
    VALUE IN HEALTH, 2020, 23 : S44 - S44
  • [34] HR+/HER2-metastatic breast cancer ADC Sacituzumab-Govitecan more beneficial than conventional chemotherapy
    Warpakowski, Andrea
    BREAST CARE, 2025, 20 (01)
  • [35] CCNE1 and PLK1 Mediate Resistance to Palbociclib in HR+/HER2-Metastatic Breast Cancer
    Guerrero-Zotano, Angel
    Belli, Stefania
    Zielinski, Christoph
    Gil-Gil, Miguel
    Fernandez-Serra, Antonio
    Ruiz-Borrego, Manuel
    Gil, Eva Maria Ciruelos
    Pascual, Javier
    Munoz-Mateu, Montserrat
    Bermejo, Begon
    Vila, Mireia Margeli
    Anton, Antonio
    Murillo, Laura
    Nissenbaum, Bella
    Liu, Yuan
    Herranz, Jesus
    Fernandez-Garcia, Daniel
    Caballero, Rosalia
    Lopez-Guerrero, Jose Antonio
    Bianco, Roberto
    Formisano, Luigi
    Turner, Nicholas
    Martin, Miguel
    CLINICAL CANCER RESEARCH, 2023, 29 (08) : 1557 - 1568
  • [36] Impact of hormone receptor expression level in HR+/HER2-metastatic breast cancer in the large French ESME cohort
    Alexandre, Marie
    Castan, Florence
    Rouge, Thibault De La Motte
    Mailliez, Audrey
    Brain, Etienne
    Bachelot, Thomas
    Arnedos, Monica
    Dalenc, Florence
    Ferrero, Jean-Marc
    Massard, Vincent
    Desmoulins, Isabelle
    Mouret-Reynier, Marie-Ange
    Levy, Christelle
    Goncalves, Anthony
    Berghian, Anca
    Savoye, Aude-Marie
    Frenel, Jean-Sebastien
    Bosquet, Lise
    Delaloge, Suzette
    Jacot, William
    CANCER RESEARCH, 2024, 84 (09)
  • [37] Clinical Outcomes with First-line Endocrine Therapy or Chemotherapy in Postmenopausal HR+/HER2-Metastatic Breast Cancer
    Song, Yan
    Hao, Yanni
    Macalalad, Alexander R.
    Lin, Peggy L.
    Signorovitch, James E.
    Wu, Eric Q.
    BREAST CANCER-BASIC AND CLINICAL RESEARCH, 2015, 9 : 67 - 72
  • [38] Ribociclib Improves Overall Survival in HR+/HER2-Metastatic Breast Cancer Across Common Genomic and Clinical Subtypes
    Jacobson, Anne
    ONCOLOGIST, 2022, 27 : S11 - S12
  • [39] Monitoring of Hematologic, Cardiac, and Hepatic Function in Post-Menopausal Women with HR+/HER2-Metastatic Breast Cancer
    Guerin, Annie
    Goldschmidt, Debbie
    Small, Tania
    Gagnon-Sanschagrin, Patrick
    Romdhani, Hela
    Gauthier, Genevieve
    Kelkar, Sneha
    Wu, Eric Q.
    Niravath, Polly
    Dalal, Anand A.
    ADVANCES IN THERAPY, 2018, 35 (08) : 1251 - 1264
  • [40] Advancing treatment choices: CDK4/6 inhibitor switching in HR+/HER2-metastatic breast cancer
    Zagami, Paola
    Esposito, Angela
    Salimbeni, Beatrice Taurelli
    Giachetti, Pier Paolo Maria Berton
    Scafetta, Roberta
    Lambertini, Matteo
    Di Maio, Massimo
    Curigliano, Giuseppe
    Criscitiello, Carmen
    Cinieri, Saverio
    BREAST, 2025, 79
12345